Increased risk of hospitalisation and intensive care admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway, December 2020 -May 2021.
<h4>Introduction</h4>Since their emergence, SARS-CoV-2 variants of concern (VOC) B.1.1.7 and B.1.351 have spread worldwide. We estimated the risk of hospitalisation and admission to an intensive care unit (ICU) for infections with B.1.1.7 and B.1.351 in Norway, compared to infections wit...
Guardado en:
Autores principales: | Lamprini Veneti, Elina Seppälä, Margrethe Larsdatter Storm, Beatriz Valcarcel Salamanca, Eirik Alnes Buanes, Nina Aasand, Umaer Naseer, Karoline Bragstad, Olav Hungnes, Håkon Bøås, Reidar Kvåle, Karan Golestani, Siri Feruglio, Line Vold, Karin Nygård, Robert Whittaker |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/742b254d266341d0acbdb33576c473fa |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7
por: Robert J. Fischer, et al.
Publicado: (2021) -
Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins
por: Maryam Hojjat Jodaylami, et al.
Publicado: (2021) -
SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains
por: Peter Radvak, et al.
Publicado: (2021) -
Author Correction: Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins
por: Maryam Hojjat Jodaylami, et al.
Publicado: (2021) -
CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2
por: Donata Hoffmann, et al.
Publicado: (2021)